Retinal Diseases, Roche Presents New Data on Faricimab - JIJI PRESSRetinal Diseases, Roche Presents New Data on Faricimab
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
VOYAGER Data Highlight Real-World Vabysmo Outcomes in Wet AMD, DME, and RVO
Key Takeaways VOYAGER real-world data showed visual and anatomical improvements with Vabysmo in treatment-naive eyes across wet AMD, DME, and RVO, while previously treated eyes generally maintained or improved vision alongside anatomical improvements Reductions in subretinal and intraretinal fluid were observed across the study cohorts in both previously untreated and previously treated eyes Patients with wet AMD and DME received fewer Vabysmo…
Roche reports VOYAGER real-world Vabysmo results across major retinal conditions at EURETINA 2026
Data from the global VOYAGER study show visual and anatomical outcomes in nAMD, DME and RVO across previously untreated and treated eyes, with no new safety signals reported IN BRIEFKEY TAKEAWAYS Roche has presented new real-world results from the VOYAGER … Read the full press release →
Giornale Radio
Roche announced today the new data from the study 'Voyager', which evaluates the efficacy, durability and safety of fariximab in neovascular-related macular degeneration (NAMD), diabetic macular oedema (Dme) and retinal venous occlusion (Rvo). In all analysed cohorts, data confirm the efficacy in the real-world of fariximab in line with Phase III results: previously untreated patients show an improvement in vision and robust improvement in retin…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
